Shah R, Simonett JM, Lyons RJ, et al. - Researchers conducted this retrospective case series to assess the disease course in pentosan polysulfate sodium (PPS)-associated maculopathy after drug cessation. The sample consisted of female patients (n = 11) diagnosed with PPS-associated maculopathy with at least 6 months of follow-up after drug cessation who were treated at the Emory Eye Center, Atlanta, Georgia, or the Casey Eye Institute, Portland, Oregon. There was no evidence of disease regression in any eye in this case series of 11 adults observed for at least 6 months after pentosan polysulfate sodium cessation. Fundus autofluorescence imaging showed expansion of the area of tissue involved in most eyes, including area of retinal pigment epithelium atrophy, and optical coherence tomography showed collapse of nodular lesions at the retinal pigment epithelium level. Such results indicate that the maculopathy related to pentosan polysulfate sodium may continue to evolve after cessation of the drug.